Impact of stereoselectivity on the pharmacokinetics and pharmacodynamics of antiarrhythmic drugs

Clinical Pharmacokinetics

Volumn 41, Issue 8, 2002, Pages 533-558

  Mehvar, R ^a   Brocks, D R ^b   Vakily, M ^c  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b UNIVERSITY OF ALBERTA   (Canada)

^c TAP PHARMACEUTICAL PRODUCTS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIARRHYTHMIC AGENT; DISOPYRAMIDE; ENCAINIDE; FLECAINIDE; MEXILETINE; PROPAFENONE; TOCAINIDE; VERAPAMIL;

ANTIARRHYTHMIC ACTIVITY; CHIRALITY; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG METABOLISM; GLOMERULUS FILTRATION RATE; HEART ARRHYTHMIA; HUMAN; LIVER METABOLISM; PRIORITY JOURNAL; REVIEW; STEREOCHEMISTRY; URINARY EXCRETION;

EID: 0036324727     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-200241080-00001     Document Type: Review

References (95)

1. Enantioselective aspects of drug action and disposition: Therapeutic pitfalls
2. Enantiomer specific pharmacokinetics
3. Stereochemical aspects of drug action and disposition
4. Stereoselective effects of disopyramide enantiomers in humans
5. Genetically determined stereoselective excretion of encainide in humans and electrophysiologic effects of its enantiomers in canine cardiac Purkinje fibers
6. Resolution of flecainide acetate, N-(2-piperidylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)-benzamide acetate, and antiarrhythmic properties of the enantiomers
7. Resolution and electrophysiological effects of mexiletine enantiomers
8. Stereoselective effects of mexiletine enantiomers on sodium currents and excitability characteristics of adult skeletal muscle fibers
9. Comparative pharmacokinetics and clinical pharmacology of propafenone enantiomers after oral administration to man
10. Stereoselective disposition and pharmacologic activity of propafenone enantiomers
11. Stereoselective interaction of tocainide and its chiral analogs with the sodium channels in human myoballs
12. Stereoselectivity in central analgesic action of tocainide and its analogs
13. Relationship between the stereoselective negative inotropic effects of verapamil enantiomers and their binding to putative calcium channels in human heart
14. The effect of dextro-, levo-, and racemic verapamil on atrioventricular conduction in humans
15. Stereoselective and non-stereoselective inhibition exhibited by the enantiomers of verapamil
16. Effects of verapamil enantiomers and major metabolites on the cytotoxicity of vincristine and daunomycin in human lymphoma cell lines
17. Reliability of antiarrhythmic drug plasma concentration monitoring
18. Antiarrhythmic drugs
19. Active secretion and enterocytic drug metabolism barriers to drug absorption
20. The absence of stereoselective P-glycoprotein-mediated transport of R/S-verapamil across the rat jejunum
21. Structural requirements for activity of propafenone-type modulators in P-glycoprotein-mediated multidrug resistance
22. Pharmacokinetics of mexiletine enantiomers in healthy human subjects: A study of the in vivo serum protein binding, salivary excretion and red blood cell distribution of the enantiomers
23. Serum binding of tocainide and its enantiomers in human subjects
24. Stereoselective serum protein binding of mexiletine enantiomers in man
25. Stereoselective pharmacokinetics of disopyramide enantiomers in man
26. Comparative pharmacokinetics of unbound disopyramide enantiomers following oral administration of racemic disopyramide in humans
27. Apparent stereoselectivity in propafenone uptake by human and rat erythrocytes
28. Pharmacokinetics of (+)-, (-)-, and (±)-verapamil after intravenous administration
29. Stereoselective protein binding of verapamil enantiomers
30. Influence of metabolites on protein binding of verapamil enantiomers
31. Protein binding of propranolol and verapamil enantiomers in maternal and foetal serum
32. Enantioselective binding analysis of verapamil to plasma lipoproteins by capillary electrophoresis-frontal analysis
33. Enantioselective binding of propranolol, disopyramide, and verapamil to human alpha(1)-acid glycoprotein
34. Enantioselective distribution of verapamil and norverapamil into human and rat erythrocytes: The role of plasma protein binding
35. Enantioselective tissue distribution of the basic drugs disopyramide, flecainide and verapamil in rats: Role of plasma protein and tissue phosphatidylserine binding
36. Tissue distribution of mexiletine enantiomers in rats
37. Stereoselective metabolism and pharmacokinetics of disopyramide enantiomers in humans
38. In vitro assessment of stereoselective hepatic metabolism of disopyramide in humans: Comparison with in vivo data
39. Interspecies differences in enantioselective mono-N-dealkylation of disopyramide by human and mouse liver microsomes
40. Identification of CYP3A4 as the enzyme involved in the mono-N- dealkylation of disopyramide enantiomers in humans
41. Stereoselective disposition of flecainide in relation to the sparteine/debrisoquine metaboliser phenotype
42. Stereoselective hydroxylation of mexiletine in human liver microsomes: Implication of P450IID6 -a preliminary report
43. Role of polymorphic debrisoquin 4-hydroxylase activity in the stereoselective disposition of mexiletine in humans
44. In vitro characterization of the human cytochrome P-450 involved in polymorphic oxidation of propafenone
45. Enantiomer/enantiomer interaction of (S)- and (R)-propafenone for cytochrome P450IID6-catalyzed 5-hydroxylation: In vitro evaluation of the mechanism
46. Effect of selective serotonin reuptake inhihitors on the oxidative metabolism of propafenone: In vitro studies using human liver microsomes
47. Identification and characterization of the cytochrome P450 enzymes involved in N-dealkylation of propafenone: Molecular base for interaction potential and variable disposition of active metabolites
48. Analysis and stereoselective metabolism after separate oral doses of tocainide enantiomers to healthy volunteers
49. Regiochemistry and enantioselectivity in the oxidative N-dealkylation of verapamil
50. Predictability of the in vivo metabolism of verapamil from in vitro data: Contribution of individual pathways and stereoselective aspects
51. Identification of P450 enzymes involved in metabolism of verapamil in humans
52. Cytochrome P450 isoforms involved in metabolism of the enantiomers of verapamil and norverapamil
53. Stereoselective pharmacokinetics of disopyramide and interaction with cimetidine
54. Enantioselective steady-state kinetics of unbound disopyramide and its dealkylated metabolite in man
55. In vivo interaction of the enantiomers of disopyramide in human subjects
56. Stereoselective disposition and metabolism of disopyramide in pediatric patients
57. Stereoselective genetically-determined interaction between chronic flecainide and quinidine in patients with arrhythmias
58. Stereoselective pharmacokinetics of tocainide in human uraemic patients and in healthy subjects
59. Antiarrhythmic activity, electrocardiographic effects and pharmacokinetics of the encainide metabolites O-desmethyl encainide and 3-methoxy-O-desmethyl encainide in man
60. Differential stereoselective metabolism of metoprolol in extensive and poor debrisoquine metabolizers
61. Stereoselective disposition of mexiletine in man
62. The pharmacokinetics of the enantiomers of mexiletine in humans
63. Stereoselective disposition of the antiarrhythmic agent mexiletine during the concomitant administration of caffeine
64. Pharmacokinetic and pharmacodynamic interaction between mexiletine and propafenone in human beings
65. An enantiomer-enantiomer interaction of (S)- and (R)-propafenone modifies the effect of racemic drug therapy
66. Stereoselective steady state disposition and action of propafenone in Chinese subjects
67. The influence of CYP2D6 activity on the kinetics of propafenone enantiomers in Chinese subjects
68. Stereoselective pharmacokinetics of propafenone and its major metabolites in healthy Chinese volunteers
69. Fluoxetine impairs the CYP2D6-mediated metabolism of propafenone enantiomers in healthy Chinese volunteers
70. Food increases the bioavailability of propafenone
71. Serum tocainide enantiomer concentrations in human subjects
72. The pharmacokinetics of (R)- and (S)-tocainide in patients with acute ventricular arrhythmias
73. Stereospecific salivary excretion of tocainide enantiomers in man
74. Stereoselective first-pass metabolism of highly cleared drugs; studies of the bioavailability of L- and D-verapamil examined with a stable isotope technique
75. Interaction of verapamil and cimetidine: Stereochemical aspects of drug metabolism, drug disposition and drug action
76. Aging effects of stereoselective pharmacokinetics and pharmacodynamics of verapamil
77. Stereoselective verapamil disposition and dynamics in aging during racemic verapamil administration
78. Aging of women alters (S)-verapamil pharmacokinetics and pharmacodynamics
79. Verapamil stereoisomerism: Enantiomeric ratios in plasma dependent on peak concentrations, oral input rate, or both
80. Effects of verapamil on P-R intervals in relation to verapamil plasma levels following single i.v. and oral administration and during chronic treatment
81. Effects of d,l-verapamil on atrioventricular conduction in relation to its stereoselective first-pass metabolism
82. Effect of grapefruit juice on pharmacokinetics and pharmacodynamics of verapamil enantiomers in healthy volunteers
83. Verapamil stereoisomers during racemic verapamil administration: Effects of aging and comparisons to administration of individual stereoisomers
84. Age and gender related changes in stereoselective pharmacokinetics and pharmacodynamics of verapamil and norverapamil
85. Input rate-dependent stereoselective pharmacokinetics: Enantiomeric oral bioavailability and blood concentration ratios after constant oral input
86. Input rate-dependent stereoselective pharmacokinetics: Effect of pulsatile oral input
87. Input rate-dependent stereoselective pharmacokinetics: Experimental evidence in verapamil-infused isolated rat livers
88. Pharmacokinetics of verapamil and norverapamil enantiomers after administration of immediate and controlled-release formulations to humans: Evidence suggesting input-rate determined stereoselectivity
89. No effect of high-protein food on the stereoselective bioavailability and pharmacokinetics of verapamil
90. The effect of food, time of dosing, and body position on the pharmacokinetics and pharmacodynamics of verapamil and norverapamil
91. Absorption and disposition of a new anfiarrhythmic agent bidisomide in man
92. The effects of the stereoisomers of propafenone and diprafenone in guinea-pig heart
93. Enantioselective determination of diprafenone in human plasma
94. Pharmacokinetics of pirmenol enantiomers and pharmacodynamics of pirmenol racemate in patients with premature ventricular contractions
95. Single- and multiple-dose pharmacokinetics of (R)-(-)-and (S)-(+)- prenylamine in man